近日,有机构表示,医药板块估值经历较长时间调整,近期已呈现显著结构性修复趋势,2025年在支持引导商保发展的政策背景下,支付端有望边际改善,创新药械有望获益。其中,医药投融资有望复苏,二级市场行情回暖驱动一级市场投融资回升,CXO及上游景气度持续向好。而这种向好的趋势也体现在近期企业披露的三季报中。根据梳理,近期包括药明康德、泰格医药、九洲药业、博腾股份、康龙化成等一批医药CXO企业已经公布三季报...
Source Link近日,有机构表示,医药板块估值经历较长时间调整,近期已呈现显著结构性修复趋势,2025年在支持引导商保发展的政策背景下,支付端有望边际改善,创新药械有望获益。其中,医药投融资有望复苏,二级市场行情回暖驱动一级市场投融资回升,CXO及上游景气度持续向好。而这种向好的趋势也体现在近期企业披露的三季报中。根据梳理,近期包括药明康德、泰格医药、九洲药业、博腾股份、康龙化成等一批医药CXO企业已经公布三季报...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.